Oscar Health (OSCR) Cash & Equivalents (2020 - 2026)

Oscar Health's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $4.8 billion for Q1 2026.

• Quarterly Cash & Equivalents rose 114.85% year-over-year to $4.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 114.85% YoY) and the FY2025 annual result came in at $2.8 billion, up 81.65% from the prior year.
• Cash & Equivalents was $4.8 billion for Q1 2026 at Oscar Health, up from $2.8 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $4.8 billion in Q1 2026 and bottomed at $1.2 billion in Q3 2024.
• A 5-year average of $2.2 billion and a median of $2.1 billion in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 33.75% — and 2026, when it jumped 114.85%.
• Oscar Health's Cash & Equivalents stood at $1.6 billion in 2022, then increased by 20.0% to $1.9 billion in 2023, then decreased by 18.35% to $1.5 billion in 2024, then surged by 81.65% to $2.8 billion in 2025, then jumped by 73.21% to $4.8 billion in 2026.
• Business Quant data shows OSCR's Cash & Equivalents at $4.8 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.1 billion in Q3 2025.